An evidence-based review of pregabalin for the treatment of fibromyalgia

Arnold, Lesley M.; Choy, Ernest; Clauw, Daniel J.; Oka, Hiroshi; Whalen, Ed; Semel, David; Pauer, L.; Knapp, Lloyd

doi:10.1080/03007995.2018.1450743

Cited by 27 publications

(27 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cooper et al 27 considered scarce the evidence of the benefit of gabapentin at doses between 1200 and 2400 mg/day in antalgic therapy for FM compared to placebo, although the majority of patients reported a sensation of overall improvement. While there is evidence of improvement in pain, sleep, and general activities when patients with FM use pregabalin at daily doses of 300-600mg/day, which were significantly higher than those receiving placebo 7,[23][24][25] . Both gabapentinoid drugs are usually well tolerated, dizziness and drowsiness are usually the most commonly reported adverse reactions 23,27 .…”

Section: Pharmacological Interventionsmentioning

confidence: 96%

“…Among the anticonvulsants, pregabalin and gabapentin are the most commonly used. Although both have structural similarity with the gamma-aminobutyric acid neurotransmitter (GABA), they have no action in this pathway, but in voltage-dependent calcium channels 7,23 . These anticonvulsants bind to the al-pha2-delta subunits of calcium channels.…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

“…These anticonvulsants bind to the al-pha2-delta subunits of calcium channels. However, it remains unknown how they act precisely to benefit the clinical manifestations in FM 23 . The most accepted current postulate suggests that in this syndrome there would be glutamatergic hyperactivity which, in turn, would be controlled by blocking calcium influx at presyn-aptic terminals by pregabalin action 26 .…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

See 2 more Smart Citations

The current treatment of fibromyalgia

Júnior

Almeida²

2018

Brazilian Journal of Pain

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES: Fibromyalgia is a highly relevant theme for research considering its impressive 2% worldwide prevalence, diffuse pain and suffering, largely unknown pathophysiology, scarce odds of cure and, more often than not, poor symptom control. This study aims to review the main options of treatment for fibromyalgia, including some novel alternatives. CONTENTS: The pharmacological treatment for fibromyalgia can be prescribed in monotherapy or combination of drugs, which comprises antidepressants, muscle relaxants, anticonvulsants, cannabinoids, opioids, N-methyl D-Aspartate antagonists, melatoninergic agonists, peptidergic substances among others. Non-pharmacological therapies include acupuncture, behavioral (or psychobehavioral) and psychological (or psychotherapy) interventions, physical activity programs, hyperbaric oxygen therapy, ozone therapy, transcranial magnetic stimulation, stretching exercises associated to low intravenous curare doses, among others. Treatment modalities are presented according to possible mechanisms of action, level of scientific evidence and recommendation. CONCLUSION: Fibromyalgia therapy should be individualized, and it does not aim the cure. Its objective is to reduce the subject's suffering; provide function improvement and, as much as possible, the individual's autonomy and quality of life. There is much in common in most approach recommendations, yet there are some divergence and changes as knowledge is acquired about a theme where consensus is far from being achieved.

show abstract

Section: Pharmacological Interventionsmentioning

confidence: 96%

Section: Pharmacological Interventionsmentioning

confidence: 99%

Section: Pharmacological Interventionsmentioning

confidence: 99%

See 1 more Smart Citation

The current treatment of fibromyalgia

Júnior

Almeida²

2018

Brazilian Journal of Pain

View full text Add to dashboard Cite

show abstract

“…Pregabalin and gabapentin are the most commonly used anticonvulsants. Despite both having structural similarity with the gamma-aminobutyric acid neurotransmitter (GABA), they have no action on this pathway, but in voltage-dependent calcium channels [15,21]. These anticonvulsants bind to the alpha2-delta subunits of calcium channels.…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

“…These anticonvulsants bind to the alpha2-delta subunits of calcium channels. However, it remains unknown how they act exactly for the benefit of clinical manifestations in FM [21].…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

Fibromyalgia Syndrome: Clinical Review at the Look of the Physiotherapy Academic

Barros¹,

Costa²,

Nascimento³

et al. 2020

IJEAS

View full text Add to dashboard Cite

Fibromyalgia syndrome is a disease characterized by diffuse chronic pain, sleep disorder, depression and fatigue, which alters the quality of life of the individual, and acupuncture is a treatment option that already has satisfactory results in improving quality of life of individuals submitted to technique. Therefore, this study aims to highlight the benefits of physiotherapy in reducing pain pictures of individuals with fibromyalgia syndrome, evidencing the importance of physiotherapeutic treatment, simultaneously with the follow-up of pharmacological treatment. The methods used for this work were based on the methodology of the experimental factorial planning article: A brief review, published in the journal International Journal of Advanced Engineering Research and Science (IJAERS). Based on references, it is seen that the quality of life of patients with fibromyalgia syndrome is closely related to pain, stress, emotional exhaustion, depression and quality of life. Physiotherapy combined with pharmacological interventions presents satisfactory results promoting the reduction of symptoms of fibromyalgia. We can conclude that drug interventions in conjunction with physiotherapeutic

show abstract